<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144220</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB-50627</org_study_id>
    <nct_id>NCT02144220</nct_id>
  </id_info>
  <brief_title>Remote Access to Care, Everywhere, for Parkinson Disease</brief_title>
  <acronym>RACE-PD</acronym>
  <official_title>Remote Access to Care, Everywhere: Using Telemedicine to Deliver Patient-centered Care to Patients With Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Davis Phinney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the feasibility, efficacy and the value of
      providing care to individuals with Parkinson disease directly into their homes. The specific
      aims are:

        1. To demonstrate the feasibility of conducting remote evaluations of patients with
           Parkinson disease nationally;

        2. To measure the impact of remote care on each patient's ability to improve his or her
           quality of life (QoL) and better manage his or her Parkinson disease; and

        3. To assess the long-term acceptability to patients in receiving ongoing care remotely via
           telemedicine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>6 months</time_frame>
    <description>The percent of telemedicine visits completed as scheduled. (Goal &gt;80%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quality of Life as Measured by the PDQ-39 Assessment Tool</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The impact on Quality of life (QoL) as measured by the change in PDQ-39 score from baseline to 6 months. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>6 months</time_frame>
    <description>- The percent of patients participated who stated that they are interested in receiving ongoing care for their PD via telemedicine. (Goal &gt;80%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility (Descriptive)</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of physician visits where the physician was were satisfied or very satisfied with the virtual visit overall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Felt That the Recommendations Improved Their Health</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Virtual care visit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-time virtual care visit for Parkinson disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Virtual care visit</intervention_name>
    <description>Video-conferencing visit with a Parkinson disease specialist</description>
    <arm_group_label>Virtual care visit</arm_group_label>
    <other_name>Telemedicine visit</other_name>
    <other_name>Virtual house call</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 30

          -  Self reported diagnosis of idiopathic Parkinson disease

          -  Ability to converse in English

          -  Ability and willingness to provide informed consent and complete study requirements

          -  Access to a non-public computer or similar devices with broadband internet.

          -  Located in New York, Maryland, Delaware, California, or Florida at time of virtual
             visit (or veterans with Parkinson disease anywhere in the U.S.)

        Exclusion Criteria:

          -  Any condition (e.g.prominent psychosis) that in the investigator's or coordinator's
             judgment would preclude participation.

          -  Concurrent enrollment in another telemedicine study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Ray Dorsey, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco/San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dorsey ER, Venkataraman V, Grana MJ, Bull MT, George BP, Boyd CM, Beck CA, Rajan B, Seidmann A, Biglan KM. Randomized controlled clinical trial of &quot;virtual house calls&quot; for Parkinson disease. JAMA Neurol. 2013 May;70(5):565-70. doi: 10.1001/jamaneurol.2013.123.</citation>
    <PMID>23479138</PMID>
  </reference>
  <reference>
    <citation>Venkataraman V, Donohue SJ, Biglan KM, Wicks P, Dorsey ER. Virtual visits for Parkinson disease: A case series. Neurol Clin Pract. 2014 Apr;4(2):146-152.</citation>
    <PMID>24790799</PMID>
  </reference>
  <reference>
    <citation>Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. Epub 2006 Nov 2.</citation>
    <PMID>17082464</PMID>
  </reference>
  <reference>
    <citation>Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013 May 21;80(21):1989-96. doi: 10.1212/WNL.0b013e318293e2ce. Epub 2013 Apr 24. Review.</citation>
    <PMID>23616157</PMID>
  </reference>
  <reference>
    <citation>Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011 Aug 30;77(9):851-7. doi: 10.1212/WNL.0b013e31822c9123. Epub 2011 Aug 10.</citation>
    <PMID>21832214</PMID>
  </reference>
  <reference>
    <citation>Willis AW, Schootman M, Tran R, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology. 2012 Oct 23;79(17):1774-80. doi: 10.1212/WNL.0b013e3182703f92. Epub 2012 Oct 10.</citation>
    <PMID>23054239</PMID>
  </reference>
  <reference>
    <citation>The European Parkinson's Disease Association. The european parkinson's disease standards of care consensus statement. http://www.kompetenznetzparkinson.de/EPDA_Parkinson_s_Standard_nsus_Statement_Vol_I.pdf&gt;2013.</citation>
  </reference>
  <reference>
    <citation>Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M, George BP, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Dorsey ER. Telemedicine for the care of nursing home residents with Parkinson's disease. Mov Disord. 2009 May 15;24(7):1073-6. doi: 10.1002/mds.22498.</citation>
    <PMID>19353687</PMID>
  </reference>
  <reference>
    <citation>Dorsey ER, Deuel LM, Voss TS, Finnigan K, George BP, Eason S, Miller D, Reminick JI, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Biglan KM. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease. Mov Disord. 2010 Aug 15;25(11):1652-9. doi: 10.1002/mds.23145.</citation>
    <PMID>20533449</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <results_first_submitted>November 10, 2016</results_first_submitted>
  <results_first_submitted_qc>November 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2017</results_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Ray Dorsey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Telemedicine</keyword>
  <keyword>Virtual care visit</keyword>
  <keyword>Remote visit</keyword>
  <keyword>Video-conferencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was primarily online through mass email messaging from the Davis Phinney Foundation, internet listings on Fox Trial Finder, messages from PatientsLikeMe, Google AdWords in eligible states, and outreach to support groups.</recruitment_details>
      <pre_assignment_details>Individuals indicated their interest in participating by either visiting the Davis Phinney Foundation’s “funded research” web page where individuals completed an online screening survey or by contacting study coordinators by phone or email.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Virtual Care Visit</title>
          <description>One-time virtual care visit for Parkinson disease.
Virtual care visit: Video-conferencing visit with a Parkinson disease specialist</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>technology incompatibility</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Virtual Care Visit</title>
          <description>One-time virtual care visit for Parkinson disease.
Virtual care visit: Video-conferencing visit with a Parkinson disease specialist</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="277"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility</title>
        <description>The percent of telemedicine visits completed as scheduled. (Goal &gt;80%)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Virtual Care Visit</title>
            <description>One-time virtual care visit for Parkinson disease.
Virtual care visit: Video-conferencing visit with a Parkinson disease specialist</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility</title>
          <description>The percent of telemedicine visits completed as scheduled. (Goal &gt;80%)</description>
          <units>percentage of visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Quality of Life as Measured by the PDQ-39 Assessment Tool</title>
        <description>The impact on Quality of life (QoL) as measured by the change in PDQ-39 score from baseline to 6 months. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson’s disease-specific health related quality over the last month. 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better quality of life.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Virtual Care Visit</title>
            <description>One-time virtual care visit for Parkinson disease.
Virtual care visit: Video-conferencing visit with a Parkinson disease specialist</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life as Measured by the PDQ-39 Assessment Tool</title>
          <description>The impact on Quality of life (QoL) as measured by the change in PDQ-39 score from baseline to 6 months. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson’s disease-specific health related quality over the last month. 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better quality of life.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-1.5" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acceptability</title>
        <description>- The percent of patients participated who stated that they are interested in receiving ongoing care for their PD via telemedicine. (Goal &gt;80%)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Virtual Care Visit</title>
            <description>One-time virtual care visit for Parkinson disease.
Virtual care visit: Video-conferencing visit with a Parkinson disease specialist</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability</title>
          <description>- The percent of patients participated who stated that they are interested in receiving ongoing care for their PD via telemedicine. (Goal &gt;80%)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility (Descriptive)</title>
        <description>Percentage of physician visits where the physician was were satisfied or very satisfied with the virtual visit overall.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Virtual Care Visit</title>
            <description>One-time virtual care visit for Parkinson disease.
Virtual care visit: Video-conferencing visit with a Parkinson disease specialist</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility (Descriptive)</title>
          <description>Percentage of physician visits where the physician was were satisfied or very satisfied with the virtual visit overall.</description>
          <units>percentage of visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Felt That the Recommendations Improved Their Health</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Virtual Care Visit</title>
            <description>One-time virtual care visit for Parkinson disease.
Virtual care visit: Video-conferencing visit with a Parkinson disease specialist</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Felt That the Recommendations Improved Their Health</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Virtual Care Visit</title>
          <description>One-time virtual care visit for Parkinson disease.
Virtual care visit: Video-conferencing visit with a Parkinson disease specialist</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ray Dorsey, MD</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-0663</phone>
      <email>ray.dorsey@chet.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

